JP2019514358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514358A5 JP2019514358A5 JP2018552822A JP2018552822A JP2019514358A5 JP 2019514358 A5 JP2019514358 A5 JP 2019514358A5 JP 2018552822 A JP2018552822 A JP 2018552822A JP 2018552822 A JP2018552822 A JP 2018552822A JP 2019514358 A5 JP2019514358 A5 JP 2019514358A5
- Authority
- JP
- Japan
- Prior art keywords
- rrs
- vector
- nucleotide sequence
- nucleic acid
- sequence encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 108020004707 nucleic acids Proteins 0.000 claims description 99
- 102000039446 nucleic acids Human genes 0.000 claims description 99
- 239000002773 nucleotide Substances 0.000 claims description 89
- 125000003729 nucleotide group Chemical group 0.000 claims description 89
- 102100030355 Host cell factor 1 Human genes 0.000 claims description 64
- 239000003550 marker Substances 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 102000025171 antigen binding proteins Human genes 0.000 claims description 16
- 108091000831 antigen binding proteins Proteins 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 208000005229 Autosomal recessive Robinow syndrome Diseases 0.000 claims description 7
- 238000001945 resonance Rayleigh scattering spectroscopy Methods 0.000 claims description 7
- 102000018120 Recombinases Human genes 0.000 claims description 6
- 108010091086 Recombinases Proteins 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 37
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022137796A JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2024144352A JP7789143B2 (ja) | 2016-04-20 | 2024-08-26 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 | |
| US62/325,385 | 2016-04-20 | ||
| PCT/US2017/028552 WO2017184831A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137796A Division JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514358A JP2019514358A (ja) | 2019-06-06 |
| JP2019514358A5 true JP2019514358A5 (https=) | 2020-05-28 |
| JP7134868B2 JP7134868B2 (ja) | 2022-09-12 |
Family
ID=58701850
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552822A Active JP7134868B2 (ja) | 2016-04-20 | 2017-04-20 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2022137796A Active JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2024144352A Active JP7789143B2 (ja) | 2016-04-20 | 2024-08-26 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022137796A Active JP7546015B2 (ja) | 2016-04-20 | 2022-08-31 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
| JP2024144352A Active JP7789143B2 (ja) | 2016-04-20 | 2024-08-26 | 発現強化座位の使用に基づく抗体を作製するための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11530277B2 (https=) |
| EP (1) | EP3445780A1 (https=) |
| JP (3) | JP7134868B2 (https=) |
| KR (2) | KR102474757B1 (https=) |
| CN (2) | CN116004544A (https=) |
| AR (1) | AR108295A1 (https=) |
| AU (2) | AU2017253240B2 (https=) |
| BR (1) | BR112018071285A2 (https=) |
| CA (1) | CA3015371A1 (https=) |
| EA (1) | EA201892137A1 (https=) |
| IL (2) | IL262268B2 (https=) |
| MX (2) | MX2018012866A (https=) |
| SG (2) | SG11201807881VA (https=) |
| TW (1) | TW201803981A (https=) |
| WO (1) | WO2017184831A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018071285A2 (pt) | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores, vetor, sistema, e, método |
| IL275462B2 (en) * | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| WO2020084034A1 (en) * | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
| AU2019403279A1 (en) * | 2018-12-21 | 2021-07-01 | Genentech, Inc. | Targeted integration of nucleic acids |
| JP7250950B2 (ja) | 2019-03-29 | 2023-04-03 | エフ． ホフマン－ラ ロシュ アーゲー | 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法 |
| JP7522100B2 (ja) | 2019-04-02 | 2024-07-24 | 中外製薬株式会社 | 標的特異的な外来遺伝子の導入方法 |
| EP3986924A1 (en) * | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3140323A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| AU2020294879A1 (en) | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CN118547004A (zh) * | 2019-06-19 | 2024-08-27 | 豪夫迈·罗氏有限公司 | 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法 |
| CN114008212B (zh) * | 2019-06-19 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 通过以限定的组织形式靶向整合多个表达盒来产生三价抗体表达细胞的方法 |
| AU2020308002A1 (en) * | 2019-06-26 | 2022-01-20 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| EP4087925A2 (en) * | 2020-01-10 | 2022-11-16 | F. Hoffmann-La Roche AG | Method for the assembly of large nucleic acids from short fragments |
| TW202342755A (zh) * | 2021-12-22 | 2023-11-01 | 美商建南德克公司 | 多載體重組酶介導的匣式交換 |
| TW202528546A (zh) | 2023-09-07 | 2025-07-16 | 美商再生元醫藥公司 | 經共價表面修飾之腺相關病毒的生產及純化 |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| TW202540433A (zh) | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| EA005921B1 (ru) | 2000-08-07 | 2005-08-25 | Женсет | Ген и белок, ассоциированные с шизофренией |
| GB0209884D0 (en) | 2002-04-30 | 2002-06-05 | Ares Trading Sa | Proteins |
| ES2439874T3 (es) | 2002-05-29 | 2014-01-27 | Regeneron Pharmaceuticals, Inc. | Sistema de expresión en eucariotas inducible |
| WO2004046340A2 (en) | 2002-11-14 | 2004-06-03 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| EP2115136A4 (en) | 2006-12-21 | 2010-05-19 | Glaxosmithkline Llc | NOVEL PROCEDURE |
| WO2008089396A1 (en) | 2007-01-19 | 2008-07-24 | Invitrogen Corporation | Compositions and methods for genetic manipulation and monitoring of cell lines |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| US8409838B2 (en) | 2009-06-02 | 2013-04-02 | Regeneron Pharmaceuticals, Inc. | Fucosylation-deficient cells |
| MY192182A (en) * | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| EP2478013B1 (en) | 2009-09-16 | 2018-10-24 | F.Hoffmann-La Roche Ag | Coiled coil and/or tether containing protein complexes and uses thereof |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| HUE047278T2 (hu) | 2011-08-05 | 2020-04-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TW202423993A (zh) | 2012-11-14 | 2024-06-16 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| BR112017008022A2 (pt) * | 2014-10-23 | 2018-02-20 | Regeneron Pharmaceuticals, Inc. | célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse. |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| BR112018071285A2 (pt) | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores, vetor, sistema, e, método |
-
2017
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko active Active
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Ceased
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en not_active Ceased
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
-
2018
- 2018-10-19 MX MX2024014381A patent/MX2024014381A/es unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP7546015B2/ja active Active
- 2022-11-10 US US18/054,350 patent/US12503520B2/en active Active
-
2023
- 2023-12-04 IL IL309065A patent/IL309065B1/en unknown
-
2024
- 2024-08-26 JP JP2024144352A patent/JP7789143B2/ja active Active
- 2024-09-26 AU AU2024220126A patent/AU2024220126A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514358A5 (https=) | ||
| JP7253020B2 (ja) | キメラ抗原受容体およびその使用 | |
| CN106011104B (zh) | 利用拆分Cas系统进行基因编辑和表达调控方法 | |
| JP2019515666A5 (https=) | ||
| CN108778291B (zh) | 包含重组t细胞受体的组合物和文库以及使用重组t细胞受体的方法 | |
| JP2019150066A5 (https=) | ||
| JP2021534770A5 (https=) | ||
| Howitt et al. | Adenovirus interaction with its cellular receptor CAR | |
| JP2022534282A5 (https=) | ||
| CN109071633A (zh) | 基于使用表达增强性基因座来制备抗体的组合物和方法 | |
| JP2018505174A (ja) | キメラ抗原受容体、組成物及び方法 | |
| CN111315761A (zh) | 用于选择性转导靶细胞的基于衔接子的逆转录病毒载体系统 | |
| JP2018533963A5 (https=) | ||
| CN107428816A (zh) | 针对肿瘤抗原ny‑eso‑1的mhc i和mhc ii‑限制表位的癌症的组合t细胞受体基因疗法 | |
| KR20170012324A (ko) | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 | |
| CN110996658B (zh) | 包含人源化asgr1基因座的非人动物 | |
| CN105177031A (zh) | 嵌合抗原受体修饰的t细胞及其用途 | |
| CN106117354A (zh) | 一种全人源抗CD47的全分子IgG抗体及其应用 | |
| JP2014517690A5 (https=) | ||
| EP2663643A1 (en) | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scfv) | |
| CN102250952B (zh) | 介导外源基因在哺乳动物细胞高效表达的载体及其应用 | |
| CN104745596B (zh) | 靶向肝癌细胞的细胞制备物 | |
| JP2008505626A5 (https=) | ||
| CN106467576A (zh) | 一种抗体融合蛋白及其制备方法与应用 | |
| CN109280674B (zh) | 一种筛选抗体的非人模式动物的构建方法及其应用 |